thyroid nodules and thyroid cancer
Always start with TSH + neck ultrasound. Low TSH → radionuclide scan (hyperfunctioning “hot” nodules are almost never malignant — do not FNA). Normal/high TSH → risk-stratify by ACR TI-RADS to decide FNA (TR3 ≥2.5 cm, TR4 ≥1.5 cm, TR5 ≥1.0 cm). In differentiated thyroid cancer (ATA 2025), de-escalate: lobectomy is sufficient for many low-risk tumours, and long-term TSH suppression is no longer suggested for low/intermediate-risk patients with an excellent response.
Anaplastic thyroid cancer (rapidly enlarging, rock-hard neck mass with stridor/dysphagia → urgent airway + core biopsy + rapid BRAF V600E). Before any surgery for medullary thyroid cancer, exclude phaeochromocytoma (metanephrines) to prevent intraoperative hypertensive crisis.
initial nodule workup — TSH first
flowchart TD
A["palpable or incidental thyroid nodule"] --> B["serum TSH + diagnostic thyroid/neck US"]
B --> C{"TSH suppressed?"}
C -- yes --> D["¹²³I or ⁹⁹mTc thyroid scan"]
D --> E{"hyperfunctioning\n(hot) nodule?"}
E -- yes --> F["NO FNA — treat hyperthyroidism\n(RAI, surgery, or ATD)"]
E -- no (cold / isofunctioning) --> G["ACR TI-RADS US stratification"]
C -- no (normal / high) --> G
G --> H{"meets TI-RADS\nsize threshold?"}
H -- yes --> I["US-guided FNA → Bethesda I–VI"]
H -- no --> J["US surveillance or no follow-up"]
- Do not measure routine serum thyroglobulin for nodule diagnosis (non-specific; used only for post-treatment DTC surveillance). Measure serum calcitonin only if suspicious for medullary thyroid cancer (family history of MTC/MEN2, suggestive cytology) — not routinely in North America.
- High-risk clinical features (lower threshold for FNA/workup): childhood head/neck radiation, family history of thyroid cancer / MEN2 / Cowden / FAP, rapid growth, hoarseness/vocal cord palsy, fixed firm nodule, cervical lymphadenopathy, or FDG-PET–avid thyroid incidentaloma (~30–40% malignancy risk).
ACR TI-RADS ultrasound stratification
Points are summed across 5 features — highest-suspicion features include solid composition (2), markedly hypoechoic (3), taller-than-wide shape (3), lobulated/irregular margins (2) or extrathyroidal extension (3), and punctate echogenic foci / microcalcifications (3).
| ACR TI-RADS | points | suspicion (cancer risk) | FNA threshold | US follow-up threshold |
|---|---|---|---|---|
| TR1 | 0 | benign (≤2%) | no FNA | none |
| TR2 | 2 | not suspicious (≤2%) | no FNA | none |
| TR3 | 3 | mildly suspicious (~5%) | ≥2.5 cm | ≥1.5 cm (1, 3, 5 y) |
| TR4 | 4–6 | moderately suspicious (5–20%) | ≥1.5 cm | ≥1.0 cm (1, 2, 3, 5 y) |
| TR5 | ≥7 | highly suspicious (≥20%) | ≥1.0 cm | ≥0.5 cm (annual × 5 y) |
- Purely cystic and spongiform nodules (TR1) do not need FNA regardless of size (drain only if symptomatic).
- ATA 2015 vs ACR TI-RADS: ATA 2015 uses slightly lower cut-offs for intermediate/low suspicion (1.0 / 1.5 cm); ACR TI-RADS (2.5 / 1.5 / 1.0 cm) is standard in Canadian radiology reporting and cuts unnecessary biopsies.
bethesda cytology categories
| category | risk of malignancy | next step |
|---|---|---|
| I — non-diagnostic | 5–10% | repeat US-guided FNA |
| II — benign | <3% | no intervention; US follow-up only if high-suspicion US or growth |
| III — AUS / FLUS | ~10–30% | repeat FNA, molecular testing, or diagnostic lobectomy |
| IV — follicular neoplasm | ~25–40% | molecular testing or diagnostic lobectomy (FNA cannot distinguish adenoma from carcinoma) |
| V — suspicious for malignancy | ~50–75% | surgery (lobectomy or total thyroidectomy) |
| VI — malignant | >97% | surgery (or active surveillance for selected T1a papillary microcarcinoma <1 cm) |
differentiated thyroid cancer (ATA 2025)
DTC (~90% papillary, ~10% follicular/oncocytic) has excellent prognosis; ATA 2025 emphasises de-escalation to avoid overtreatment.
- Initial therapy:
- Active surveillance: option for selected intrathyroidal papillary microcarcinomas (cT1aN0M0, ≤1 cm).
- Lobectomy: sufficient for many low-risk cT1–T2 N0 M0 DTCs (lower hypoparathyroidism and RLN injury than total thyroidectomy).
- Total thyroidectomy ± selective RAI: high-risk or selected intermediate-risk disease (gross ETE, clinically positive nodes, distant metastases, aggressive histology). NIFTP is not considered thyroid cancer (lobectomy alone, no RAI, no TSH suppression).
- Dynamic response-to-therapy & TSH targets (ATA 2025 vs ATA 2015):
- Excellent response (low/intermediate risk, undetectable Tg / negative neck US): TSH within the normal reference range after both total thyroidectomy and lobectomy (ATA 2025 shifts away from the older ATA 2015 0.5–2.0 mU/L band to avoid unnecessary LT4 after lobectomy, atrial fibrillation, and osteoporosis).
- Indeterminate response: TSH within normal reference range per ATA 2025 (ATA 2015 suggested mild suppression 0.1–0.5 mU/L).
- Biochemical or structural incomplete response: TSH below the normal reference range per ATA 2025 (individualised for progression vs cardiac/bone risk; ATA 2015 used 0.1–0.5 mU/L for biochemical incomplete and <0.1 mU/L for structural incomplete — no extra benefit below <0.03 mU/L).
- Surveillance: serum thyroglobulin (Tg) + anti-Tg antibodies (anti-TgAb interferes with Tg assays — rising TgAb acts as a surrogate marker) + neck ultrasound.
medullary and anaplastic thyroid cancer
- Medullary thyroid cancer (MTC) (parafollicular C-cells; ~25% hereditary via RET mutations):
- Before any MTC surgery: measure calcitonin, CEA, serum calcium, and plasma/urine metanephrines (rule out phaeochromocytoma first so anaesthesia does not trigger hypertensive crisis!).
- Offer germline RET testing to every patient with MTC → MEN2A / MEN2B.
- RAI does not work (C-cells do not concentrate iodine) and TSH suppression is not indicated (replace to normal TSH).
- Anaplastic thyroid cancer (ATC): rapidly enlarging, rock-hard neck mass with stridor/dysphagia in an older adult — airway emergency; immediate core biopsy + rapid BRAF V600E testing (dabrafenib + trametinib if BRAF-mutated) + multidisciplinary oncology/palliative care.
Prepared 2026-11-19. Not yet verified — check every number against the sources.